Theravance Biopharma P/E Ratio

Theravance Biopharma posts a P/E ratio of 15.99. That is below the Healthcare sector average of 26.85. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a P/E ratio near 26.85 is typical. Theravance Biopharma's 15.99 is lower that level. That is roughly 40.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Theravance Biopharma's P/E ratio of 15.99 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for TBPH's P/E ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 26.85), and (3) consistency with growth and profitability. This page covers the first two; Theravance Biopharma's other metric pages and overview cover the third.

Judging Theravance Biopharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in P/E ratio easier to interpret. Start with 15.99 here, then scan peer and history charts to see if the gap is persistent.